Caribou Biosciences offers the strongest allogeneic CAR-T data to date, with efficacy and safety. Read why I am bullish about ...
-- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $184 million in cash, cash equivalents, and marketable securities expected to fund the Company’s ...
Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $0.38 per share a year ago. These ...
Caribou Biosciences, Inc. (NASDAQ:CRBU) is included in our list of the 7 most volatile stocks under $5 for day trading. On February 2, 2026, Clear Street began covering Caribou Biosciences, Inc.
BERKELEY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will ...
-- CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate pivotal Phase 3 trial in 2L LBCL by YE 2024 -- -- CB-011 CaMMouflage Phase 1 ...
BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results